COSCIENS Abandons Biopharma Unit Following Macrilen Pediatric Setback

COSCIENS Biopharma’s decision to pull the plug on its German operations marks a definitive end to its direct pursuit of the biopharmaceutical development market. For years, the company’s value proposition was anchored in Macrilen (macimorelin), the first and only FDA and EMA-approved oral test for adult growth hormone deficiency (AGHD). While the product successfully reached the market for adults, the commercial reality was stark: the biopharmaceutical business unit consistently operated at a loss. Management had long signaled that the path to profitability required a significant expansion of the addressable market, specifically into the pediatric population where growth hormone deficiency diagnosis is more frequent and clinically critical.

The failure of the Phase 3 DETECT trial was the primary catalyst for this strategic retreat. In the high-stakes world of orphan drug and diagnostic development, a single late-stage clinical failure can be terminal for smaller players. The DETECT trial was designed to prove Macrilen’s efficacy in children, a demographic that would have provided the necessary volume to offset the high costs of maintaining a global biopharmaceutical infrastructure. However, the data did not support a clear path to approval. A subsequent Type C meeting with the FDA confirmed the worst-case scenario: the regulatory hurdles for a full pediatric approval in the United States were now insurmountable within the company’s current capital structure and timeline.

“

For years, the company’s value proposition was anchored in Macrilen (macimorelin), the first and only FDA and EMA-approved oral test for adult growth hormone deficiency (AGHD).

This move into insolvency for the German subsidiaries—Aeterna Zentaris GmbH and Zentaris IVF GmbH—is described as a 'structured' exit. It suggests that while the parent company is stopping the financial bleeding, it is also looking to salvage what value remains in the intellectual property and existing commercial contracts. The company had recently inked a distribution deal with Wuzhou Drug International Trading Limited, indicating that there is still some international interest in the Macrilen asset. However, a distribution agreement is a low-margin endeavor compared to the full-scale biopharma operations COSCIENS was previously maintaining. By offloading the operational costs and liabilities of the German units, COSCIENS is effectively transitioning from a development-heavy biopharma firm to a leaner entity, likely focused on managing remaining licenses or pivoting to a new strategic direction altogether.